<code id='E3E8B13471'></code><style id='E3E8B13471'></style>
    • <acronym id='E3E8B13471'></acronym>
      <center id='E3E8B13471'><center id='E3E8B13471'><tfoot id='E3E8B13471'></tfoot></center><abbr id='E3E8B13471'><dir id='E3E8B13471'><tfoot id='E3E8B13471'></tfoot><noframes id='E3E8B13471'>

    • <optgroup id='E3E8B13471'><strike id='E3E8B13471'><sup id='E3E8B13471'></sup></strike><code id='E3E8B13471'></code></optgroup>
        1. <b id='E3E8B13471'><label id='E3E8B13471'><select id='E3E8B13471'><dt id='E3E8B13471'><span id='E3E8B13471'></span></dt></select></label></b><u id='E3E8B13471'></u>
          <i id='E3E8B13471'><strike id='E3E8B13471'><tt id='E3E8B13471'><pre id='E3E8B13471'></pre></tt></strike></i>

          Home / fashion / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:84949

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In